<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
  <channel>
    <title>Arrowhead Research Corporation</title>
    <link>http://www.arrowres.com/</link>
    <description>Arrowhead Research Corp.: Nanotech with a point</description>
    <language>en-us</language>
    <copyright>Copyright 2005, Arrowhead Research Corporation</copyright>
    <pubDate>Fri, 25 Sep 2009</pubDate>
    <lastBuildDate>Fri, 25 Sep 2009</lastBuildDate>
    <ttl>60</ttl>
    <image>
      <url>http://www.arrowres.com/images/links/logo_about1.gif</url>
      <title>Arrowhead Research Corporation</title>
      <link>http://www.arrowres.com/</link>
      <width>100</width>
      <height>88</height>
      <description>Arrowhead Research Corp.: Nanotech with a point</description>
    </image>

	<item>
		<title>ARROWHEAD ANNOUNCES CLOSING OF $8.65 MILLION REGISTERED DIRECT OFFERING</title>
		<link>http://www.arrowheadresearch.com/publications/june23_2010.html</link>
		<description>Pasadena, CA  June 23, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has closed its previously announced registered direct offering of 6.6 million shares of common stock and warrants to purchase 3.3 million shares of common stock.</description>
		<pubDate>Wed, 23 Jun 2010 12:00:00 PST</pubDate>
	</item>
	
	<item>
		<title>ARROWHEAD ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS</title>
		<link>http://www.arrowheadresearch.com/publications/june17_2010.html</link>
		<description>Pasadena, CA  June 17, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced and received firm commitments for a registered direct offering to raise $8.65 million through the sale of 6.6 million shares of its common stock, and warrants to purchase 3.3 million shares of common stock.</description>
		<pubDate>Tue, 17 Jun 2010 11:30:00 PST</pubDate>
	</item>
	
	<item>
		<title>ARROWHEAD TO HOLD ANNUAL MEETING JUNE 16, 2010; CEO PRESENTATION AVAILABLE VIA WEBCAST</title>
		<link>http://www.arrowheadresearch.com/publications/june15_2010.html</link>
		<description>PASADENA, Calif. June 15, 2010 Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Annual Meeting of Stockholders will be held on Wednesday, June 16, 2010 at 10:00 am PT at the Sheraton Pasadena, 303 E. Cordova Street, Pasadena, CA.</description>
		<pubDate>Wed, 15 Jun 2010 12:25:00 PST</pubDate>
	</item>
	<item>
		<title>ARROWHEAD TO REJOIN THE RUSSELL MICROCAP INDEX</title>
		<link>http://www.arrowheadresearch.com/publications/june14_2010.html</link>
		<description>PASADENA, Calif. June 14, 2010 Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will join the Russell Microcapฎ Index when Russell Investments reconstitutes its family of U.S. indexes, according to a preliminary list of additions posted June 11 on www.russell.com.</description>
		<pubDate>Mon, 14 Jun 2010 11:00:00 PST</pubDate>
	</item>
	
	<item>
		<title>ARROWHEAD PORTFOLIO COMPANY, LEONARDO BIOSYSTEMS, RECEIVES $2.5 MILLION FUNDING FROM TEXAS EMERGING TECHNOLOGY FUND</title>
		<link>http://www.arrowheadresearch.com/publications/june7_2010.html</link>
		<description>PASADENA, Calif.June 7, 2010Arrowhead Research Corporation (Nasdaq: ARWR) announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies.</description>
		<pubDate>Mon, 7 Jun 2010 9:30:00 PST</pubDate>
	</item>
	
	<item>
		<title>ARROWHEAD RESEARCH ANNOUNCES CLINICAL DATA PRESENTATIONS AT THE 2010 ASCO ANNUAL MEETING ON JUNE 6, 2010</title>
		<link>http://www.arrowheadresearch.com/publications/june01_2010.html</link>
		<description>PASADENA, Calif. - June 1, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that interim data from the phase 1 clinical trial conducted by its majority-owned subsidiary, Calando Pharmaceuticals, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.</description>
		<pubDate>Tue, 1 Jun 2010 9:30:00 PST</pubDate>
	</item>

	<item>
		<title>ARROWHEAD TO PRESENT AT NOBLE FINANCIAL SIXTH ANNUAL EQUITY CONFERENCE</title>
		<link>http://www.arrowheadresearch.com/publications/may28_2010.html</link>
		<description>PASADENA, Calif.  May 28, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Noble Financial Sixth Annual Equity Conference at 10:30 a.m. EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida.</description>
		<pubDate>Wed, 28 May 2010 8:15:00 PST</pubDate>
	</item>
	
	
	<item>
		<title>Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals siRNA drug delivery platform featured in Houston Chronicle</title>
		<link>http://www.arrowheadresearch.com/publications/may27_2010.html</link>
		<description>PASADENA, Calif.  May 27, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that two articles of interest to Arrowhead stockholders appeared in the Houston Chronicle this week.</description>
		<pubDate>Wed, 27 May 2010 11:10:00 PST</pubDate>
	</item>


	<item>
		<title>Unidym and Guardian Industries Form Partnership to Develop and Commercialize Carbon Coated Glass Products</title>
		<link>http://www.arrowheadresearch.com/publications/may19_2010.html</link>
		<description>Sunnyvale, CA - Unidym, a majority owned subsidiary of Arrowhead Research (NASDAQ: ARWR), announced today that it has entered an agreement with global glass manufacturer Guardian Industries to develop and commercialize carbon coated glass products for touch screen devices and other applications.</description>
		<pubDate>Wed, 19 May 2010 11:20:00 PST</pubDate>
	</item>
	
	<item>
		<title>ARROWHEAD REPORTS FISCAL 2010 SECOND QUARTER FINANCIAL RESULTS</title>
		<link>http://www.arrowheadresearch.com/publications/may13_2010.html</link>
		<description>PASADENA, Calif.  Arrowhead Research Corporation (NASDAQ: ARWR)today announced financial results for its fiscal 2010 second quarter ended March 31, 2010.</description>
		<pubDate>Thu, 13 May 2010 12:00:00 PST</pubDate>
	</item>
	
	
	<item>
		<title>Arrowhead Advertorial</title>
		<link>http://www.arrowheadresearch.com/pdf/Arrowhead-Fortune_May_2010.pdf</link>
		<description>As seen in Fortune, May 24, 2010 issue</description>
		<pubDate>Thu, 13 May 2010 11:00:00 PST</pubDate>
	</item>
	
	
	<item>
		<title>Arrowhead Research to Report Second Quarter Fiscal 2010 Financial Results and Host Conference Call on Thursday, May 13, 2010</title>
		<link>http://www.arrowheadresearch.com/publications/may7_2010.html</link>
		<description>PASADENA, Calif.  May 7, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 second quarter ended March 31, 2010, on Thursday, May 13, 2010, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).</description>
		<pubDate>Fri, 7 May 2010 6:00:00 PST</pubDate>
	</item>
	
	<item>
		<title>Arrowhead Announces The Appointment of Former FDA Commissioner And National Cancer Institute Director Dr. Andrew Von Eschenbach to Its Board of Advisors</title>
		<link>http://www.arrowheadresearch.com/publications/april26_2010.html</link>
		<description>PASADENA, Calif.April 26, 2010Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Andrew von Eschenbach to its Scientific Advisory Board (SAB).</description>
		<pubDate>Mon, 26 April 2010 12:00:00 PST</pubDate>
	</item>

	<item>
		<title>Arrowhead to Present at Upcoming Conferences</title>
		<link>http://www.arrowheadresearch.com/publications/april20_2010.html</link>
		<description>PASADENA, Calif.April 20, 2010Arrowhead Research Corporation (Nasdaq: ARWR) announced today that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the following investor conferences</description>
		<pubDate>Tue, 20 April 2010 12:30:00 PST</pubDate>
	</item>
	
	<item>
		<title>Arrowhead Regains Compliance with Rule 5550, NASDAQ $1.00 Minimum Bid Requirement</title>
		<link>http://www.arrowheadresearch.com/publications/april15_2010.html</link>
		<description>PASADENA, Calif.  April 15, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on April 14, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company has regained compliance with NASDAQ Rule 5550(a)(2) in that the Company's closing bid price has been at $1.00 per share or greater for at least 10 consecutive business days.</description>
		<pubDate>Thu, 15 April 2010 12:00:00 PST</pubDate>
	</item>

	<item>
		<title>CNT-Enabled Touch Sensitive MP-4 Players Based on Unidyms Printable CNT Films Displayed at China Electronics Fair</title>
		<link>http://www.arrowheadresearch.com/publications/april12_2010.html</link>
		<description>Sunnyvale, CA  Unidym, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that touch sensitive MP-4 players enabled by Unidyms transparent conductive films were displayed at the 75th China Electronics Fair.</description>
		<pubDate>Mon, 12 April 2010 12:30:00 PST</pubDate>
	</item>

	<item>
		<title>Arrowhead Announces The Appointment of Nobel Laureate Dr. Leland Hartwell to Its Board of Advisors</title>
		<link>http://www.arrowheadresearch.com/publications/april7_2010.html</link>
		<description>PASADENA, Calif.April 7, 2010Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Lee Hartwell to its Scientific Advisory Board.</description>
		<pubDate>Wed, 7 April 2010 11:10:00 PST</pubDate>
	</item>
	
	<item>
		<title>Breaking the cell barrier</title>
		<link>http://www.arrowres.com/pdf/Arrowhead_ProdDev_040510.pdf</link>
		<description>The publication of data from a Phase I trial of CALAA-01
provided the first proof of concept in man that systemically
delivered short interfering RNA can be targeted to specific cells.</description>
		<pubDate>Mon, 5 April 2010 12:10:00 PST</pubDate>
	</item>


<item>
		<title>White Paper</title>
		<link>http://www.arrowres.com/pdf/CalandoReport.pdf</link>
		<description>CALAA-01 Results Show Delivery Technology to Meet Critical Need in RNAi
Therapeutics, Putting Arrowhead in Position to Monetize Asset.</description>
		<pubDate>Mon, 5 April 2010 12:05:00 PST</pubDate>
	</item>

	<item>
		<title>Arrowhead Research Subsidiary, Calando Pharmaceuticals, Provides First Proof of RNA Interference in Humans with Systemically Administered siRNA Therapeutic; Clinical Trial Results Published in Nature</title>
		<link>http://www.arrowres.com/publications/march22_2010.html</link>
		<description>&lt;p&gt;PASADENA, Calif.  March 22, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc. has demonstrated systemic delivery of siRNA and the successful "silencing" of a widely recognized cancer gene via RNA interference (RNAi) in humans.&lt;/p&gt;</description>
		<pubDate>Mon, 22 March 2010 11:00:00 PST</pubDate>
	</item>

	<item>
		<title>Caltech-led Team Provides Proof in Humans of RNA Interference Using Targeted Nanoparticles</title>
		<link>http://media.caltech.edu/press_releases/13334</link>
		<description>PASADENA, Calif.A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticleused as an experimental therapeutic and injected directly into a patients bloodstreamcan traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).</description>
		<pubDate>Sun, 21 March 2010 12:20:00 PST</pubDate>
	</item>
	
	<item>
		<title>Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement </title>
		<link>http://www.arrowres.com/publications/march19_2010.html</link>
		<description>&lt;p&gt;PASADENA, Calif.  March 18, 2010  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on March 16, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until September 13, 2010, to regain compliance with NASDAQ's $1.00 minimum bid requirement.&lt;/p&gt;</description>
		<pubDate>Tue, 18 March 2010 11:40:00 PST</pubDate>
	</item>
	
	<item>
		<title>Arrowhead Reports Fiscal 2010 First Quarter Financial Results</title>
		<link>http://www.arrowres.com/publications/february11_2010.html</link>
		<description>&lt;p&gt;PASADENA, Calif.  Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 first quarter ended December 31, 2009.&lt;/p&gt;</description>
		<pubDate>Tue, 11 Febr 2010 12:00:00 PST</pubDate>
	</item>
	
	<item>
		<title>Arrowhead Research to Report First Quarter Fiscal 2010 Financial Results and Host Conference Call on Thursday, February 11, 2010</title>
		<link>http://www.arrowres.com/publications/february08_2010.html</link>
		<description>&lt;p&gt;PASADENA, Calif. - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 first quarter ended December 31, 2009, on Thursday, February 11, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 877-941-4774 or 480-629-9760. Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com.&lt;/p&gt;</description>
		<pubDate>Mon, 08 Febr 2010 10:00:00 PST</pubDate>
	</item>

	  <item>
		<title>Unidym Adds Malcolm Gillis, Ph.D. to Board of Directors</title>
		<link>http://www.arrowres.com/publications/february08_2010_unidym.html</link>
		<description>&lt;p&gt;Sunnyvale, CA - Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that Malcolm Gillis, Ph.D. has been appointed to its Board of Directors. Dr. Gillis served as the President of William Marsh Rice University from 1993 until 2004 and guided Rice to become a leader in the then emerging field of nanoscience. His distinguished academic career focused on economics and environmental public policy and included appointments at Duke University and Harvard University.&lt;/p&gt;</description>
		<pubDate>Mon, 08 Febr 2010 12:10:00 PST</pubDate>
	</item>

	  <item>
		<title>Arrowhead's Portfolio Company, Nanotope, Publishes Preclinical Data Demonstrating Cartilage Regeneration</title>
		<link>http://www.arrowres.com/publications/february02_2010.html</link>
		<description>&lt;p&gt;PASADENA, Calif. - February 2, 2010 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration. The study's authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope's bioactive nanofiber system promotes the growth of new cartilage in a rabbit model.&lt;/p&gt;</description>
		<pubDate>Tue, 02 Febr 2010 11:30:00 PST</pubDate>
	</item>
	
	
    <item>
		<title>Unidym Announces Joint Venture to Market Printable CNT Electronics in Korea</title>
		<link>http://www.arrowres.com/publications/fabruary02_2010.html</link>
		<description>&lt;p&gt;Sunnyvale, CA  Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has signed a definitive agreement to create a joint venture partnership with Wisepower, a publicly traded Korean company (KOSDAQ: 040670), to market and co-develop Unidyms proprietary film and electronic ink products into the Korean touch panel and display industries.&lt;/p&gt;</description>
		<pubDate>Mon, 01 Febr 2010 12:40:00 PST</pubDate>
	</item>
	
    <item>
		<title>Unidym Completes Licensing Agreements to Expand Use of its Carbon Nanotube IP in Diverse Array of Applications</title>
		<link>http://www.arrowres.com/publications/jan20.html</link>
		<description>&lt;p&gt;Sunnyvale, CA  Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has completed three licensing agreements for its nanotechnology intellectual property (IP) for use in applications such as aerospace and military products.&lt;/p&gt;</description>
		<pubDate>Wed, 20 Jan 2010 11:00:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Research Corporation Subsidiary Tego Biosciences Sells IP Portfolio to Luna Innovations</title>
		<link>http://www.arrowres.com/publications/december28.html</link>
		<description>&lt;p&gt;PASADENA, California  December 28, 2009  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its wholly owned subsidiary, Tego Biosciences, has completed a definitive asset purchase agreement for the sale of its non-cash intellectual property (IP) to Luna Innovations, Inc. (Nasdaq: LUNA), a developer and manufacturer of new-generation products that include pharmaceutical nanomedicines.&lt;/p&gt;</description>
		<pubDate>Mon, 28 Dec 2009 11:10:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Reports Fiscal 2009 Fourth Quarter and Full-Year Financial Results</title>
		<link>http://www.arrowres.com/publications/december23.html</link>
		<description>&lt;p&gt;PASADENA, Calif.  December 22, 2009  Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2009 fourth quarter and full-year ended September 30, 2009.&lt;/p&gt;</description>
		<pubDate>Wed, 23 Dec 2009 12:00:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Research to Report Fiscal 2009 Fourth Quarter and Year-End Financial Results and Host Conference Call on Tuesday, December 22, 2009</title>
		<link>http://www.arrowres.com/publications/december21.html</link>
		<description>&lt;p&gt;PASADENA, Calif.  December 21, 2009  Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2009 fourth quarter and year ended September 30, 2009, on Tuesday, December 22, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).&lt;/p&gt;</description>
		<pubDate>Mon, 21 Dec 2009 11:00:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Announces $3.2 Million Private Placement</title>
		<link>http://www.arrowres.com/publications/december17.html</link>
		<description>&lt;p&gt;PASADENA, California - December 17, 2009 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has raised approximately $3.2 million in gross proceeds from a private placement of approximately 5.0 million units.&lt;/p&gt;</description>
		<pubDate>Tue, 17 Dec 2009 12:30:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Subsidiary, Unidym, Enters Into Joint Development Agreement With a Major Liquid Crystal Display (LCD) Manufacturer For Glass Based Liquid Crystal Displays</title>
		<link>http://www.arrowres.com/publications/december14.html</link>
		<description>&lt;p&gt;Sunnyvale, CA - Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has entered into a joint development agreement with a major liquid crystal display (LCD) manufacturer.&lt;/p&gt;</description>
		<pubDate>Mon, 14 Dec 2009 12:00:00 PST</pubDate>
	</item>
    <item>
		<title>Unidym and Nano-C Enter Exclusive License Agreement for Fullerene Derivatives Used in Solar Cells</title>
		<link>http://www.arrowres.com/publications/december02.html</link>
		<description>&lt;p&gt;Sunnyvale, CA - December 2, 2009 - Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has entered an exclusive license agreement with Nano-C for patents covering fullerene derivatives. The license provides Nano-C exclusive rights to U.S. Patent No. 5,739,376 and foreign counterparts in the field of photovoltaics.&lt;/p&gt;</description>
		<pubDate>Wed, 2 Dec 2009 11:30:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Subsidiary Unidym, Inc. Enters into Third Year of Joint Development Program with Samsung Electronics for Flexible Displays</title>
		<link>http://www.arrowres.com/publications/november11.html</link>
		<description>&lt;p&gt;Pasadena, CA  November 11, 2009  Arrowhead Research Corporation (NASDAQ: ARWR) announced today that its majority owned subsidiary, Unidym, Inc., has entered into a joint development agreement with Samsung Electronics Co., Ltd., a leading maker of liquid crystal display (LCD) panels, to extend their successful collaboration into a third year.&lt;/p&gt;</description>
		<pubDate>Wed, 11 Nov 2009 12:00:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Subsidiary Calando Pharmaceuticals Expands Board of Directors</title>
		<link>http://www.arrowres.com/publications/090812044647.html</link>
		<description>&lt;p&gt;Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui, Ph.D., and Bruce D. Given, MD, to its Board of Directors.&lt;/p&gt;</description>
		<pubDate>Wed, 4 Nov 2009 11:30:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead CEO Provides Update on Company Strategy and Operations</title>
		<link>http://www.arrowres.com/publications/090812044645.html</link>
		<description>&lt;p&gt;Arrowhead Research Corporation (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company's shareholders:&lt;/p&gt;</description>
		<pubDate>Tue, 3 Nov 2009 12:00:00 PST</pubDate>
	</item>
    <item>
		<title>Arrowhead Receives NASDAQ Deficiency Notice Related to Minimum Bid Price</title>
		<link>http://www.arrowres.com/publications/090925045615.html</link>
		<description>&lt;p&gt;Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has received a deficiency letter from the NASDAQ Stock Market indicating that based on the Company&amp;rsquo;s closing bid price for the last 30 consecutive business days, the Company does not comply with the $1.00 minimum bid price as set forth in NASDAQ Marketplace Rule 5550(a)(2).&lt;/p&gt;</description>
		<pubDate>Fri, 18 Sep 2009 11:00:00 PST</pubDate>
	</item>
	<item>
		<title>Arrowhead Regains Compliance with NASDAQ Listing Requirements</title>
		<link>http://www.arrowres.com/publications/090812044643.html</link>
		<description>&lt;p&gt;Arrowhead Research Corporation (NASDAQ: ARWR)&amp;nbsp; today announced that it has received notification from the NASDAQ Stock Market that the Company has regained compliance with the minimum of $2.5 million in stockholders&amp;rsquo; equity requirement for continued listing on the NASDAQ Capital Market, pursuant to NASDAQ Marketplace Rule 4310(c)(3).&lt;/p&gt;
	&lt;div id=&quot;refHTML&quot;&gt;&amp;nbsp;&lt;/div&gt;</description>
		<pubDate>Wed, 12 Aug 2009 12:00:00 PST</pubDate>
	</item>
	<item>
    <title>Arrowhead Reports Third Quarter Fiscal 2009 Financial Results</title>
    <link>http://www.arrowres.com/publications/090810132813.html</link>
    <description>&lt;p&gt;Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its third fiscal quarter ended June 30 2009.&lt;/p&gt;</description>
    <pubDate>Mon, 10 Aug 2009 11:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Announces Completion of $2.76 Million Private Placement</title>
    <link>http://www.arrowres.com/publications/090807040308.html</link>
    <description>&lt;p&gt;Arrowhead Research Corporation today announced that it has completed a second and final closing of its private offering with selected institutional and accredited investors bringing the proceeds of the offering to a total of $2.76 million.&lt;/p&gt;
&lt;div id=&quot;refHTML&quot;&gt;&amp;nbsp;&lt;/div&gt;</description>
    <pubDate>Fri, 7 Aug 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Research to Report Fiscal Third Quarter 2009 Financial Results and Host Conference Call on Monday, August 10, 2009</title>
    <link>http://www.arrowres.com/publications/090804044233.html</link>
    <description>&lt;p&gt;PASADENA, Calif. &amp;mdash; August 4, 2009 &amp;mdash; Arrowhead Research Corporation (NASDAQ: ARWR today announced that it will report its financial results for the third quarter of fiscal 2009 ended June 30, 2009, on Monday, August 10, 2009 at 4:30 p.m. ET (1:30 p.m. PT). To participate in the conference call, please dial 888-846-5003 or 480-629-9856. Investors may also access a live audio webcast of this conference call on the Company's website at &lt;a href=&quot;http://www.arrowheadresearch.com&quot; target=&quot;_blank&quot;&gt;www.arrowheadresearch.com&lt;/a&gt;.&lt;/p&gt;</description>
    <pubDate>Tue, 4 Aug 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Senior Advisors Featured in Nature and Nature Medicine Articles</title>
    <link>http://www.arrowres.com/publications/090805045152.html</link>
    <description>&lt;!โโโโโโโโโโโโโโโโโโโโโโโโโโโโโ[if gte mso 9]โโโโโโโโโโโโโโโโโโโโโโโโโโโโ&gt;  &lt;!โโโโโโโโโโโโโโโโโโโโโโโโโโโโ[endif]โโโโโโโโโโโโโโโโโโโโโโโโโโโโ&gt;&lt;!โโโโโโโโโโโโโโโโโโโโโโโโโโโโโ[if gte mso 9]โโโโโโโโโโโโโโโโโโโโโโโโโโโโ&gt;
&lt;p&gt;PASADENA, Calif. &amp;ndash; July 30, 2009 &amp;ndash; Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Scientific Advisory Board members Mauro Ferrari, Ph.D., and Chad Mirkin, Ph.D., were featured in the July 2009 editions of both Nature Medicine and Nature magazines for their outstanding work in nanomedicine.&lt;br /&gt;
&lt;meta http-equiv=&quot;Content-Type&quot; content=&quot;text/html; charset=utf-8&quot;&gt;
&lt;meta name=&quot;ProgId&quot; content=&quot;Word.Document&quot;&gt;
&lt;meta name=&quot;Generator&quot; content=&quot;Microsoft Word 11&quot;&gt;
&lt;meta name=&quot;Originator&quot; content=&quot;Microsoft Word 11&quot;&gt;                                                                                                        &lt;/meta&gt;
&lt;/meta&gt;
&lt;/meta&gt;
&lt;/meta&gt;
&lt;/p&gt;</description>
    <pubDate>Thu, 30 Jul 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Increases Ownership in &lt;br&gt;Carbon Nanotube-based Electronics Films Subsidiary Unidym Inc. to 70%</title>
    <link>http://www.arrowres.com/publications/090716043842.html</link>
    <description>&lt;p&gt;PASADENA, Calif. &amp;ndash; July 16, 2009 &amp;ndash; Arrowhead Research Corporation (NASDAQ: ARWR) (&amp;ldquo;the Company&amp;rdquo;) today announced that it has completed the first phase of a plan to increase its ownership in electronics films subsidiary, Unidym Inc., a strategy that was initially announced at its annual shareholder meeting on March 26, 2009.&lt;/p&gt;</description>
    <pubDate>Thu, 16 Jul 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Announces Private Placement of $2 Million</title>
    <link>http://www.arrowres.com/publications/090710085059.html</link>
    <description>&lt;p&gt;PASADENA, Calif. &amp;ndash; July 10, 2009 &amp;ndash; Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has obtained commitments from selected institutional and accredited investors to purchase at least $2 million of common stock and warrants in a private placement transaction.&lt;/p&gt;</description>
    <pubDate>Fri, 10 Jul 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead announces CFO Transition</title>
    <link>http://www.arrowres.com/publications/090710043205.html</link>
    <description>&lt;p&gt;Pasadena, CA &amp;mdash; Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Paul McDonnel, the Company&amp;rsquo;s Chief Financial Officer, intends to resign as the Company&amp;rsquo;s Chief Financial Officer in order pursue another opportunity out of the state.&lt;/p&gt;</description>
    <pubDate>Fri, 10 Jul 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Subsidiary Calando Pharmaceuticals Enters into  License Agreement with Cerulean Pharma Inc.</title>
    <link>http://www.arrowres.com/publications/090623044623.html</link>
    <description>&lt;p&gt;- Calando To License Cyclosert&amp;trade; Platform and Associated IT-101 Drug Candidate for Upfront Payment of $2.4 Million, Milestone Payments and Royalties from Product Sales; Agreement Creates Substantial Potential Revenue Stream -&lt;/p&gt;</description>
    <pubDate>Tue, 23 Jun 2009 12:00:00 PST</pubDate>
</item><item>
    <title>Arrowhead Reports Second Quarter Fiscal 2009 Financial Results</title>
    <link>http://www.arrowres.com/publications/090515041558.html</link>
    <description>&lt;p&gt;PASADENA, Calif.&amp;mdash;(BUSINESS WIRE)&amp;mdash;Arrowhead Research Corporation (NASDAQ:ARWR - News) today announced financial results for its second fiscal quarter ended March 31, 2009.&lt;/p&gt;</description>
    <pubDate>Fri, 15 May 2009 12:00:00 PST</pubDate>
</item>
  </channel>
</rss>